National Research Council of Canada. Human Health Therapeutics
In efﬁcacy studies using the syngeneic 4T1 TNBC model, AVID200 was shown to promote signiﬁcant T-cell inﬁltration into tumors. This inﬁltration resulted in reduced primary tumor growth as well as signiﬁcant reductions in metastatic lesions. Additionally, ex vivo studies revealed that AVID200 treatment decreased T-cell apoptosis, promoted T-cell proliferation in response to tumor cell lysates in the presence of dendritic cells, as well as increased the capacity of T-cells to speciﬁcally lyse 4T1 tumor cells. The novel computational design of AVID200 results in a trap with low pM in vitro neutralization potency for TGF-b 1 and 3. Additionally, AVID200 markedly promotes the “T-cell-inﬂamed” tumor state in vivo. Combination studies with immune checkpoint inhibitors will be presented.
European Journal of Cancer69: S105–.
28 EORTC – NCI – AACR Symposium on Molecular Targets and Cancer Therapeutics Wednesday 29 November 2016: Poster Sessions: Immunotherapy: Poster (Board P144)